Surgical gastrojejunostomy (SGJ)
ProcedureLaparoscopic gastrojejunostomy
NCT Number: NCT05561907
Gastric outlet obstruction (GOO) occurs commonly in malignancies involving the periampullary region (cancers originating in the head of the pancreas, duodenum, bile duct, or ampulla) or the distal stomach. GOO not only causes debilitating symptoms such as nausea, vomiting, inability to tolerate oral intake, and prevents adequate nutritional intake. Therefore, providing therapy for GOO is imperative to improve the quality of life, and nutritional status of these patients, as well as allow them to continue receiving their cancer treatment
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
After potential subjects are screened from the physicians' schedules, they will be assessed for further inclusion criteria. They will be presented with the informed consent form for their review. Once they have been given the opportunity to review and ask questions, they will sign the consent form and from this point will be considered enrolled into the study.
After signing the informed consent, subjects will be randomized to one of the two cohorts in a 1:1 manner.
On the day of their assigned procedures, subjects will be asked several quality of life questionnaires to obtain a baseline status.
Data will be collected during and immediately following the procedure to assess for any possible adverse events.
Follow-up data will be completed at the following timepoints: 1-day, 2-day, 3-day, 4-day, and 7-day, 30-day, 3-month, 6-month, and 1-year post-procedure.
QOL Scoring Systems GOOSS- Gastric Outlet Obstruction Symptom Score
GFS- Gut Function Score from Lowe et al 2002
Pre-Procedure Variables to Record Demographic
Clinical Parameters
Procedural Parameters
Post-procedure Hospitalization Daily Function
30 Day Outcomes
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Laparoscopic gastrojejunostomy
Endoscopic ultrasound (EUS) guided gastrojejunostomy
Time frame: 1 year
Days to initiation of solid oral intake will be measured from randomization to first day of intake of soft solid foods, as indicated by a GOOSS score of 2
Time frame: 1 year
All adverse events (AEs) occurring after treatment will be graded according to ASGE lexicon. A subject will be considered to have had an adverse event if they had one or more adverse events, and they will be considered to have had a serious adverse event (SAE) if they had one or more serious adverse events
Time frame: 1 year
Technical success is defined as adequate deployment and positioning of the stent(s) for EGJ or technical possibility to create an anastomosis for SGJ.
Time frame: 1 year
Clinical success is defined as improvement to a GOOSS score of 2 or 3 (oral intake of soft solid foods or resumption of full diet) without additional intervention.
Time frame: 1 year
Length of stay will be measured from randomization to discharge alive. All patients will be followed until discharge. Patients who die in hospital will be considered censored and time from randomization to death will be used.
Time frame: 3 months
BMI will be measured immediately prior to the procedure, and at one month and three months after the procedure.
Time frame: 3 months
Albumin levels will be measured immediately prior to the procedure, and at one month and three months after the procedure.
Time frame: 1 year
The Gastric Outlet Obstruction Symptom Score (GOOSS) scale is as follows, whereas a score of 1 is the worst and a score of 4 is the best:
GOOSS will be recorded at each of the following timepoints:
Time frame: 1 year
Gut Function Score (GFS) scale is as follows, whereas a score of 1 is the worst and a score of 3 is the best:
GFS will be recorded at each of the following timepoints:
Time frame: 30 Days
Karnofsky Performance Scale is measured on a scale of 0 to 100 as follows, with a score of 0 being the worst and a score of 100 being the best:
100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of their personal needs.
50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.
20 - Very sick; hospital admission necessary; active supportive treatment necessary.
10 - Moribund; fatal processes progressing rapidly. 0 - Dead
KPS will be recorded pre-procedure and at 30-days post-procedure.
Time frame: 30 Days
Ability to tolerate TB approved chemotherapeutic regimen
Contact information is provided by the study sponsor or research team.
Northwell Health
Other
Acronym: EAT-GO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07317076
Digestive System Diseases, Duodenal Diseases
Westmount, Quebec, Canada
View Trial DetailsNCT04813055
Acute Cholecystitis, Acute Pancreatic Fluid Collection
Milan, Italy
View Trial DetailsNCT06071507
Digestive System Diseases, Digestive System Neoplasms
Paris, France
View Trial DetailsNCT05640947
Digestive System Diseases, Fatty Liver
Bruges, Belgium
View Trial Details